Ben Zhao, Ph.D.
Ph.D. in Pharmaceutical Science, Ohio State University
Engaged in the research of drug delivery technology for 20+ years
Former FDA Senior Reviewer, CMC Expert; responsible for the approval of complex drugs, including nucleic acids, peptides, liposomes and cGMP quality system
Meng Xiaofeng Ph.D/MBA
PhD /MBA from the State University of New Jersey, Master from Shanghai Institute of Pharmaceutical Industry
More than 20 years of senior experience in the pharmaceutical industry, international regulatory registration and GMP field of authoritative experts
Good at drug development management, international regulatory registration, quality system construction and global market development. He has led the listing of many new drugs and more than 100 generic drugs in Europe and the United States, and promoted Chinese OTC softgel drugs to enter the mainstream channel in the United States
Robert J. Lee, Ph.D.
Tenured Professor, Ohio State University
Expert in liposome/nanoparticle delivery system, targeted drug delivery system, non-viral gene delivery system, and small nucleic acid delivery system
Yang Yongsheng, Ph.D.
Postdoctoral Fellow, University of Michigan
Engaged in the research on gene therapy and gene delivery system
Previously served as a senior pharmacologist at the US FDA, responsible for conducting research on biopharmaceutics and drug quality of new drugs and generic drugs, and review of bioequivalence of complex preparations and locally acting drugs
Angela Men, M.D., Ph.D.
Ph.D. in Pharmaceutical Science, Virginia State University
Clinical Medicine of Tianjin Medical University/Resident Physician at the Second Hospital of Tianjin Medical University
Previously served as a Senior, Special Approving Officer and Head of the Drug Approval Team of the US FDA Center for Drug Approval
Zhang Mengzi, Ph.D.
With more than 10 years’ experience in R&D and regulatory affairs; developed global regulatory strategic solutions for pharmaceutical and biotech companies, focusing on the regulatory framework and market in the United States and China
Holly Yang
Dual Master’s degrees in Enterprise Risk Management & Healthcare Management, Johns Hopkins University
Deutsche Bank, China Merchants Securities, Accenture, etc., with five years’ experience in corporate finance and financial affairs, focusing on accounting policies in China and the United States